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Increased nonenzymatic glycosylation of all major classes of apolipoproteins has been demonstrated
in diabetes. In this work we deal with the in vitro nonenzymatic glycosylation of apolipoprotein H,
whose role in lipid metabolism is still poorly understood and whose levels increase in diabetes.
Apolipoprotein H was isolated from human plasma and purified through a combination of affinity
chromatography and continuous elution electrophoresis. The in vitro glycosylation was performed
by incubating purified apolipoprotein H with high concentration of glucose. Our results indicate that
the in vitro nonenzymatic glycosylation has no effect on the physical properties of apolipoprotein
H, despite the fact that this apolipoprotein contains a high number of lysine residues. Since the
in vitro concentration of glucose was far higher than the levels normally found in diabetic subjects,
it is unlikely for apolipoprotein H to become glycosylated in diabetes.
1. INTRODUCTION
Nonenzymatic glycosylation of proteins is a process that
occurs in diabetes mellitus, and is related to the onset
several complications, including cataract formation
(Monnier and Cerami, 1981; Monnier et al., 1979), con-
nective tissue abnormalities (Yue et al., 1983; Kent
et al., 1985), and macrovascular disease (Witztum et al.,
1982; Gonen et al., 1981), the last being one of the major
causes of morbidity and mortality in diabetes (Kannel
and McGee, 1979).
Moreover, increased nonenzymatic glycosylation of
all major classes of apolipoproteins (apo)4 has been
demonstrated in diabetes (Curtiss and Witztum, 1985).
The functional consequences of this posttranslational
process are related to the abnormalities occurring in lipid
metabolism in diabetic subjects (Saudek and Eder, 1979;
Gabor et al., 1980). Abnormalities in lipid metabolism
and transport are among the main factors contributing to
the development of atherosclerosis in diabetic patients.
In fact glycosylated apoB renders low-density lipopro-
teins (LDL) functionally abnormal (Lopes-Virella et al.,
1988) as well as immunogenic. They are more suscep-
tible to oxidative modifications than nonglycosylated
lipoproteins (Bowie et al., 1993). Recognition of LDL by
the LDL receptor can be inhibited by various chemical
modifications of the lysine or arginine residues of apoB
(Steinbrecher and Witztum, 1984). Many studies have
highlighted the role of the lysine residues of apolipopro-
teins for various functional activities, such as receptor
recognition (Weisgraber et al., 1978; Mahley et al.,
1979), enzyme interaction and activation (Vainio et al.,
1983; Musliner et al., 1979), and lipid binding (Sparrow
and Gotto, 1982). Thus, nonenzymatic glycosylation of
specific lysine residues of the various apolipoproteins
could have a profound influence on the function of that
apolipoprotein.
Although the physical and metabolic properties of
in vitro glycosylated apolipoproteins have been studied
at length, similar investigations of apoH have not been
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performed. In this work we deal with the in vitro non-
enzymatic glycosylation of apoH, whose role in lipid
metabolism is still poorly understood and whose levels
increase in diabetes (Cassader et al., 1997).
In the present study apoH was glycosylated in vitro
in an attempt to explain why apoH levels were found to
be elevated in diabetic patients. Glycosylated apoH was
subjected to isoelectric focusing (IEF) and ion exchange
chromatography (IEC) to prove the nonenzymatic
process. Native apoH served as control.
2. MATERIALS AND METHODS
2.1. Materials
Tris, urea, Tween 20, acrylamide, and N,N'-methyl-
ene-bis-acrylamide, analytical grade, were purchased from
Bio-Rad (Milan, Italy). Gel Bond and ampholytes (pH
4 -6.5 and pH 6.5-9) were obtained from Amersham Phar-
macia (Milan, Italy); nitrocellulose sheets were from Bio-
Rad. Rabbit polyclonal antibody to apoH was kindly sup-
plied by Behring (Scoppito, Italy). Goat anti-rabbit IgG
(alkaline phosphatase conjugated), the alkaline phos-
phatase conjugate substrate kit, and trinitrobenzensulfonic
acid were purchased from Sigma (Milan, Italy). Molecu-
lar weight standards (low MW) were from Bio-Rad.
2.3. Glycosylation of apoH
Glycosylation of apoH was performed by incubat-
ing purified apoH (0.1 mg/ml) with 0.2 M glucose in
sterile PBS containing 1 mM EDTA (pH 7.4) at 37°C for
7 days (Makino et al., 1995).
2.4. SDS-PAGE and Western Blot of Native
and Glycosylated apoH
The apolipoprotein purity and the increased elec-
trophoretic mobility due to nonenzymatic glycosylation
were determined by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) on 12% poly-
acrylamide gels under nonreducing conditions. Elec-
trophoresis buffer was 25 mM Tris, 0.192 M glycine,
0.1% SDS, pH 8.3.
ApoH was then blotted after SDS-PAGE in 25 mM
Tris, 0.192 M Glycine, and 20% methanol, pH 8.3, at
295 mA for 100 min. Nitrocellulose membrane was
blocked with 4% bovin serum albumin in 10 mM Tris,
0.15 M NaCl, 0.1% Thimerosal, pH 7.6, and subse-
quently probed with the specific antibody anti-apoH
raised in the rabbit and with the secondary anti-rabbit
immunoglobulin G antibody conjugated with alkaline
phosphatase. The blot was developed with the alkaline
phosphatase conjugate substrate kit.
2.5. IEF and Western Blot of Native
and Glycosylated apoH
IEF was carried out in a Bio-Phoresis TM horizon-
tal electrophoresis cell (Bio-Rad), using a Model
3000/300 power unit. The polyacrylamide gel, T-5%,
C-3%, contained 2% ampholytes (pH 4-6.5 and 6.5-9;
3.75:1 v/v) and 3 M urea. Cathode and anode solutions
were 100 mM NaOH and 40 mM glutamic acid, respec-
tively. After prefocusing at 500 constant V for 35 min,
1 (ug of apoH was applied onto each lane. Electrophore-
sis was performed at 10 constant W for 3 hr. After IEF
was performed, the proteins were transferred overnight
at room temperature onto 0.45-(um-pore-size nitrocellu-
lose membrane by simple diffusion. After transfer, the
nitrocellulose was incubated with specific antibody anti-
apoH as described above.
2.6. Assay of Chemical Modification
The number of lysine residues modified in the apo-
lipoprotein upon glycosylation was estimated with the
trinitrobenzensulfonic acid assay (Habeed, 1966). The re-
2.2. Isolation and Purification of apoH
ApoH was isolated from human plasma and purified
through a combination of affinity chromatography and
continuous elution electrophoresis as previously de-
scribed (Gambino et al., 1996). Briefly, rabbit anti-apoH
antibodies (22 mg) were immobilized on cyanogen
bromide-activated Sepharose 6B. Normal serum samples
were diluted into 40 ml of buffer and applied to the col-
umn. ApoH bound to the column was eluted with 0.1 M
glycine, 0.05% NaN3, pH 2.5. Sample fractions were
concentrated with Centriprep-10 concentrators (Amicon
Inc., Beverly, MA) at 3000 rpm and 20°C in a Beckman-
J6B centrifuge (Beckman Instruments, Palo Alto, CA) to
a final volume of about 1 ml and subjected to continuous
elution electrophoresis.
Continuous elution electrophoresis of the proteins
(about 2.5 mg) was then performed with a Prep-Cell
(Bio-Rad) through a cylindrical gel (gel tube inside di-
ameter 37 mm; gel length 50 mm) composed of 8.5%
acrylamide, 2.7% N,N'-methylene-bis-acrylamide, and
0.1% SDS. The buffers were 0.025 M Tris, 0.192 M
glycine, and 0.1% SDS, pH 8.4. Separation was achieved
at 40 mA in about 8 hr.
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action was carried out in the presence of either potassium
thiocyanate or sodium lauryl sulfate in sodium bicarbon-
ate buffer at pH 8.5. The absorbance was read at 335 nm
against blank.
2.7. HPLC Ion-Exchange Chromatography
IEC of the apoH was performed by using an anion-
exchange column HEMA-IEC Bio 1000 DEAE (7.5x75
mm) (Alltech, Milan, Italy) connected to a Beckman
HPLC system. ApoH was applied to the anion column in
20 mM Tris, 0.01% NaN3, pH 8.0. The protein was
eluted with a linear gradient consisting of 20 mM Tris,
0.01% NaN3 pH 8.0, and 20 mM Tris, 0.01% NaN3 1 M
NaCl, pH 8.0, in 30 min. The absorbance was monitored
at 280 nm.
2.8. Dot Blot of Fractions
Rapid screening of HPLC fractions was conducted
in the Bio-Dot microfiltration apparatus (Bio-Rad). A
sheet of nitrocellulose is clamped between the gasket and
the 96-well sample template. Fifty ul of sample is al-
lowed to filter through the membrane. After the antigen
is immobilized, the nitrocellulose is incubated in 4% al-
bumin blocking solution. Nitrocellulose is subsequently
incubated with rabbit IgG anti-apoH at a 1/2000 dilution
at room temperature for 1.5 hr and then with goat IgG
anti-rabbit IgG labeled with alkaline phosphatase at a
1/6000 dilution. Dots are visualized with the procedure
contained in the Immun-Blot Assay kit (Bio-Rad).
Fig. 1. SDS-PAGE gel electrophoresis of Apo H after incubation of
glucose. Lanes 1 and 10: molecular mass markers are (from top to
bottom) 97.4, 66.2, 42.7, 31.0, 21.5, 14.4 kDa. Lane 3 contains a fresh
sample of apoH; lane 4 contains apoH incubated in the presence of
glucose; lane 5 contains apoH incubated in the absence of glucose.
These samples were run in the presence of B-mercaptoethanol. Lanes
7-9 contain the same samples run in nonreducing conditions.
ApoH incubated in the presence of glucose had no in-
crease in electrophoretic mobility when compared with
apoH incubated in the absence of glucose. From the pic-
tures it is also evident that no proteolytic cleavage had
occurred during the incubation at 37°C for 7 days. We
thought SDS-PAGE was unable to detect slight differ-
ences in molecular weight even when the samples were
run under reducing conditions.
3. RESULTS
Glucose incorporation into apoH was performed by
incubating 0.1 mg/ml of apoH with 0.2 M glucose in
PBS, pH 7.4, at 37°C for 7 days. After this incubation,
apoH was run through an SDS-polyacrylamide slab gel
in order to detect any variation in molecular weight.
Figure 1 shows that the molecular weight of glyco-
sylated apoH did not differ from that of apoH incubated
under the same conditions in the absence of glucose.
Lane 3 contains a fresh sample of apoH; lane 4 contains
apoH incubated in the presence of glucose; lane 5 con-
tains apoH incubated in the absence of glucose. These
samples were run in the presence of B-mercaptoethanol.
Lanes 7-9 contain the same samples run in nonreducing
conditions.
Figure 2 illustrates the Western blot of the gel dis-
played in Fig. 1 and probed with the specific antibodies.
Fig. 2. Western blot of apoH probed with the specific antibody. From
left to right: Lanes 1 and 10: prestained molecular mass markers
marked with black points are (from top to bottom) 106.0, 80.0, 49.5,
32.5, 27.5, 18.5 kDa. Lane 3 contains a fresh sample of apoH; lane 4
contains apoH incubated in the presence of glucose; lane 5 contains
apoH incubated in the absence of glucose. These samples were run in
the presence of B-mercaptoethanol. Lanes 7-9 contain the same
samples run in nonreducing conditions.
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The presence of modified amino groups was as-
sessed with the trinitrobenzensulfonic acid assay. The
trinitrobenzensulfonic reagent reacts rapidly with the
amino groups of proteins. The reaction was performed in
the presence of either potassium thiocyanate or sodium
lauryl sulfate in sodium bicarbonate buffer at pH 8.5. In
either case there was no difference in absorbance be-
tween apoH incubated with glucose and apoH incubated
without glucose.
Then, apoH incubated with glucose and apoH incu-
bated in the absence of glucose were analyzed through
IEF followed by Western blot. The IEF result is shown
in Fig. 3. Lane 1 contains a fresh sample of apoH; lane
2 contains apoH incubated in the presence of glucose;
lane 3 contains apoH incubated in the absence of glu-
cose. All the samples show the same number and type of
isoforms. The isoelectric point of apoH isoforms was not
altered after the incubation with 0.2 M glucose. If the
nonenzymatic glycosylation were successful, the posi-
tive charge of lysine residues would have been neutral-
ized by glucose. ApoH isoforms should have moved to-
ward more-anodic isoelectric points. The missing shift in
isoelectric point reveals that it is unlikely for apoH to be-
come nonenzymatically glycosylated.
The affinity for the anion-exchange column HEMA-
IEC did not change after incubating apoH with glucose.
Glycosylated apoH should have had greater affinity for
the anion-exchange column than native apoH. Both apoli-
poproteins had symmetrical elution peaks and did not ex-
hibit any chromatographic heterogeneity. Identification
of the peak related to apoH was performed through a dot-
blot test (data not shown).
4. DISCUSSION
Our results indicate that the in vitro nonenzymatic
glycosylation has no effects on the physical properties of
apoH, despite the fact that this apolipoprotein contains a
high number of lysine residues. The different chro-
matography techniques reveal no apparent modification
occurring on the apoH molecule. ApoH incubated in the
presence or in the absence of glucose had similar elec-
trophoretic mobility when compared after SDS-PAGE
under nonreducing conditions. In the presence of reduc-
ing agents such as (B-mercaptoethanol, the mobility of
both samples was higher, but they did not differ from
each other. Additionally, both samples had similar affin-
ity for the anion-exchange column, which was due to the
integral unmodified lysine residues. The unchanged elec-
trophoretic mobility and the similar affinity are in agree-
Fig. 3. Western blot of apoH analyzed through IEF. From left to right:
Lane 1: native apoH. Lane 2: ApoH incubated in the presence of glucose.
Lane 3: ApoH incubated in the absence of glucose.
ment with the result of IEF, where apoH incubated in the
presence of glucose shares the same pattern of isoforms
with apoH incubated in the absence of glucose. After
glycosylation of lysine residues apoH should lose its pos-
itive charge and become more negative. As a result,
apoH should move toward more-anodic regions and with
a different pattern of isoforms. The failure for apoH to
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shift toward anodic regions means that apoH is not prone
to becoming nonenzymatically glycosylated under these
conditions. Since the in vitro concentration of glucose
(0.2 M) was far higher than the levels normally found in
diabetic subjects, it is unlikely for apoH to become gly-
cosylated in diabetes. This is probably caused by the fact
that lysine residues lie in the inner side of apoH mole-
cules and are not accessible for glucose.
Many studies have demonstrated that in diabetic
plasma, apoAI, All, B, CI, E, and albumin are glyco-
sylated (Curtiss and Witztum, 1985; Garlick and Mazer,
1983). It was demonstrated that the modification of lysine
525 altered the conformation of albumin and in turn al-
tered its ability to bind bilirubin and long-chain fatty
acids (Shaklai et al., 1984). The glycosylation of proteins
could alter protein-lipid interactions. The important role
of lysine residues in apoB function and the fact that gly-
cosylation can alter this function has been amply demon-
strated (Witztum et al., 1982; Gonen et al., 1981; Makino
et al., 1995). On the contrary, apoH can retain its func-
tions even if glucose levels are too high in plasma. Its
ability to activate lipoprotein lipase both in vitro and
in vivo could make apoH play a key role in modulation of
triglyceride metabolism in diabetes. Further studies are
under way to define more precisely the relationship be-
tween plasma glucose concentration and the extent of
apoH glycosylation and as well as its functional role in
diabetes.
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